Hologic, Inc. (NASDAQ:HOLX) Shares Purchased by HighTower Advisors LLC

HighTower Advisors LLC grew its position in shares of Hologic, Inc. (NASDAQ:HOLX) by 9.8% during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 22,603 shares of the medical equipment provider’s stock after purchasing an additional 2,012 shares during the period. HighTower Advisors LLC’s holdings in Hologic were worth $1,832,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of HOLX. FMR LLC lifted its stake in Hologic by 64.0% during the 3rd quarter. FMR LLC now owns 5,572,545 shares of the medical equipment provider’s stock worth $453,940,000 after acquiring an additional 2,174,093 shares in the last quarter. Black Creek Investment Management Inc. lifted its position in shares of Hologic by 60.9% during the second quarter. Black Creek Investment Management Inc. now owns 2,338,970 shares of the medical equipment provider’s stock worth $173,669,000 after purchasing an additional 885,524 shares in the last quarter. Mackenzie Financial Corp boosted its stake in shares of Hologic by 1,023.3% in the second quarter. Mackenzie Financial Corp now owns 895,699 shares of the medical equipment provider’s stock valued at $66,506,000 after purchasing an additional 815,960 shares during the period. Marshall Wace LLP acquired a new position in shares of Hologic in the second quarter valued at approximately $39,427,000. Finally, The Manufacturers Life Insurance Company increased its stake in Hologic by 21.6% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 2,535,258 shares of the medical equipment provider’s stock worth $188,243,000 after buying an additional 450,190 shares during the period. 94.73% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

HOLX has been the subject of several research reports. UBS Group boosted their price target on shares of Hologic from $84.00 to $90.00 and gave the stock a “neutral” rating in a research note on Tuesday, November 5th. Citigroup downgraded Hologic from a “buy” rating to a “neutral” rating and cut their price target for the stock from $95.00 to $85.00 in a report on Tuesday, October 1st. Needham & Company LLC reiterated a “buy” rating and issued a $90.00 price objective on shares of Hologic in a research note on Tuesday, December 10th. Royal Bank of Canada upped their target price on shares of Hologic from $86.00 to $89.00 and gave the stock a “sector perform” rating in a research note on Tuesday, November 5th. Finally, Wolfe Research started coverage on shares of Hologic in a research note on Friday. They issued a “peer perform” rating for the company. Six equities research analysts have rated the stock with a hold rating, nine have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $89.50.

Hologic Stock Performance

Shares of HOLX stock opened at $73.65 on Friday. The stock’s 50-day moving average is $79.32 and its two-hundred day moving average is $78.59. The company has a debt-to-equity ratio of 0.49, a quick ratio of 3.03 and a current ratio of 3.69. Hologic, Inc. has a 1 year low of $70.24 and a 1 year high of $84.67. The firm has a market cap of $16.71 billion, a price-to-earnings ratio of 22.12, a PEG ratio of 2.38 and a beta of 0.96.

Hologic (NASDAQ:HOLX) last released its quarterly earnings results on Monday, November 4th. The medical equipment provider reported $1.01 EPS for the quarter, hitting the consensus estimate of $1.01. The company had revenue of $987.90 million for the quarter, compared to analyst estimates of $978.25 million. Hologic had a return on equity of 19.79% and a net margin of 19.59%. The firm’s revenue was up 4.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.89 earnings per share. Analysts predict that Hologic, Inc. will post 4.28 earnings per share for the current year.

Insider Buying and Selling

In related news, COO Essex D. Mitchell sold 24,856 shares of the business’s stock in a transaction dated Wednesday, December 4th. The stock was sold at an average price of $76.34, for a total value of $1,897,507.04. Following the transaction, the chief operating officer now owns 27,957 shares in the company, valued at $2,134,237.38. The trade was a 47.06 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. 1.75% of the stock is owned by company insiders.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.